The now-Meridian subsidiary’s former CEO, COO and regulatory affairs director reportedly delayed telling the FDA and the public about incorrect results obtained from Magellan’s LeadCare line of blood tests.

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced April-May 2016.

A new force of organizing care has begun to emerge designed specifically to restore to physicians the power and influence they've seen drain away. They're called physician practice management (PPM) companies, and they may be the hottest trend in health care. Recently, they've been among Wall St.'s favorite investments over the last couple of years. And they're beginning to attract doctors in large numbers.